Related Experiment Video
Updated: Aug 12, 2026

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).
Published on: March 6, 2018
Economic issues and the management of benign prostatic hyperplasia
1Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Insights
Benign prostatic hyperplasia (BPH) treatment incurs significant costs. Following US clinical guidelines for BPH diagnosis and management can lead to substantial financial savings without compromising patient care quality.
Area of Science:
- Urology
- Health Economics
Background:
- Benign prostatic hyperplasia (BPH) causes significant urologic symptoms and complications, leading to substantial global healthcare expenditures.
- Accurate documentation of financial spending on BPH management, particularly surgical interventions, is lacking internationally.
Purpose of the Study:
- To evaluate the potential financial savings achievable by adhering to established clinical guidelines for BPH diagnosis and management.
- To assess the impact of guideline adherence on the quality of patient care.
Main Methods:
- Review of US Department of Health and Human Services clinical guidelines for BPH (released February 8, 1994).
- Analysis of guideline recommendations regarding routine imaging of the upper urinary tract and diagnostic cystoscopy.
- Discussion of management strategies presented within the guidelines.
Main Results:
- The guidelines recommend against routine upper urinary tract imaging unless comorbidities exist.
- Diagnostic cystoscopy is not advised to guide treatment decisions for BPH.
- Adherence to these principles offers potential for significant cost reduction in BPH care.
Conclusions:
- Implementing the discussed BPH diagnostic and management strategies, as outlined in the 1994 US clinical guidelines, can yield considerable financial savings.
- These cost reductions can be achieved while maintaining or improving the quality of care for patients with BPH worldwide.
Abstract:
Enormous financial resources are expended worldwide on the treatment of the urologic complications and symptoms induced by benign prostatic hyperplasia (BPH). Even for its surgical management, where the best data exist, current international accounting of these expenditures remains very poorly documented. On February 8, 1994, the Department of Health and Human Services of the US government released clinical guidelines for the diagnosis and management of BPH. Imaging of the upper urinary tract as a routine diagnostic procedure is not recommended in these guidelines unless a comorbidity indicating its need exists. Diagnostic cystoscopy to assist in the decision of the need to treat is not recommended. Adherence to these two principles along with adherence to the strategies of management presented in the guidelines and discussed herein has the potential of achieving profound financial savings without impairing quality of care worldwide.
Related Concept Videos
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Nephrotic Syndrome II : Assessment and Medical Management
Urinary Tract Calculi III: Medical Management

